Dexcom Innovates Groundbreaking First Generative AI Platform in Glucose Biosensing

Dexcom has announced the launch of its new GenAI platform, making it the first continuous glucose monitoring (CGM) company to integrate Generative AI into glucose biosensing technology.

This new platform will analyse individual health data to uncover connections between lifestyle choices and glucose levels, providing actionable insights to improve metabolic health.

The first Dexcom product to utilise the GenAI technology is Stelo, the first over-the-counter glucose biosensor cleared by the FDA in the US. The Weekly Insights feature of Stelo has been enhanced to offer users more personalised content based on their glucose levels, activity, and sleep patterns.

This update, which started rolling out this week, will provide users with tailored tips, recommendations, and education on diet, exercise, and sleep, all integrated within the Stelo app.

Dexcom’s new platform is built on Google Cloud’s Vertex AI and Gemini models, which allow for more personalised insights that help users make informed decisions about their health.

The collaboration with Google Cloud aims to empower users to take better control of their metabolic health.

This launch further strengthens Dexcom’s position as a leader in glucose biosensing, with plans for more GenAI-powered features in the coming year. These advancements will continue to help users make proactive, informed decisions about their health.

Source: https://investors.dexcom.com/news/news-details/2024/Dexcom-Launches-the-First-Generative-AI-Platform-in-Glucose-Biosensing/default.aspx